/BBIO
BBIO Stock - BridgeBio Pharma, Inc.
Healthcare|BiotechnologyNASDAQ
$76.30+2.91%
+$2.16 (+2.91%) • Dec 19
74
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).72
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.70
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.9%upside
Target: $84.62
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BBIO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$75.54 – $77.06
TARGET (TP)$84.60
STOP LOSS$70.20
RISK/REWARD1:1.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.26
52W High$77.20
52W Low$26.55
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $221.90M | $9.30M | $77.65M | $69.72M | $8.25M |
| Gross Profit | $218.02M | $6.86M | $74.21M | $66.60M | $8.25M |
| Gross Margin | 98.3% | 73.7% | 95.6% | 95.5% | 100.0% |
| Operating Income | $-592,973,000 | $-607,370,000 | $-512,202,000 | $-576,632,000 | $-474,482,000 |
| Net Income | $-535,762,000 | $-643,202,000 | $-481,183,000 | $-562,539,000 | $-448,724,000 |
| Net Margin | -241.4% | -6913.9% | -619.7% | -806.9% | -5439.7% |
| EPS | $-2.88 | $-3.95 | $-3.35 | $-4.43 | $-4.10 |
Company Overview
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
12
92%
Hold / Neutral
1
8%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
12 Bullish1 Neutral/Bearish
Price Targets
$53
Average Target
↓ 30.9% Downside
Now
$33
Low
$53
Average
$94
High
Based on 14 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 11th 2025 | Bernstein | Initiation | Outperform | $94 |
| July 30th 2025 | Raymond James | Resumed | Outperform | $56 |
| July 21st 2025 | Truist | Initiation | Buy | $66 |
| July 14th 2025 | Jefferies | Initiation | Buy | $70 |
| July 9th 2025 | Oppenheimer | Upgrade | Outperform | $60 |
| June 17th 2025 | Wolfe Research | Initiation | Outperform | $49 |
| March 31st 2025 | Redburn Atlantic | Initiation | Buy | $50 |
| October 16th 2024 | Scotiabank | Initiation | Sector Outperform | - |
| October 3rd 2024 | Oppenheimer | Initiation | Perform | - |
| September 4th 2024 | Piper Sandler | Initiation | Overweight | $46 |
| March 21st 2024 | Raymond James | Resumed | Outperform | $45 |
| January 31st 2024 | BMO Capital Markets | Initiation | Market Perform | $37 |
| December 8th 2023 | Wells Fargo | Initiation | Overweight | - |
| November 7th 2023 | Citigroup | Initiation | Buy | $42 |
| October 24th 2023 | Cantor Fitzgerald | Initiation | Overweight | $50 |
Earnings History & Surprises
BBIOBeat Rate
39%
Last 18 quarters
Avg Surprise
+1.9%
EPS vs Estimate
Beats / Misses
7/11
Last 12 quarters
Latest EPS
$-0.95
Q4 2025
EPS Surprise History
Q1 24
-1.1%
$-0.96vs$-0.95
Q2 24
+87.5%
$-0.05vs$-0.40
Q3 24
+6.4%
$-1.02vs$-1.09
Q4 24
+16.5%
$-0.86vs$-1.03
Q1 25
-20.2%
$-1.31vs$-1.09
Q2 25
+12.0%
$-0.88vs$-1.00
Q3 25
-14.5%
$-0.95vs$-0.83
Q4 25
-8.0%
$-0.95vs$-0.88
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 27, 2026 | — | — | — | — |
Q1 2026 | Feb 19, 2026 | $-0.74 | — | — | — |
Q4 2025 | Oct 29, 2025 | $-0.88 | $-0.95 | -8.0% | ✗ MISS |
Q3 2025 | Aug 5, 2025 | $-0.83 | $-0.95 | -14.5% | ✗ MISS |
Q2 2025 | Apr 29, 2025 | $-1.00 | $-0.88 | +12.0% | ✓ BEAT |
Q1 2025 | Feb 20, 2025 | $-1.09 | $-1.31 | -20.2% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-1.03 | $-0.86 | +16.5% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $-1.09 | $-1.02 | +6.4% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $-0.40 | $-0.05 | +87.5% | ✓ BEAT |
Q1 2024 | Feb 22, 2024 | $-0.95 | $-0.96 | -1.1% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $-0.86 | $-1.08 | -25.6% | ✗ MISS |
Q3 2023 | Aug 3, 2023 | $-0.86 | $-0.98 | -14.0% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-0.84 | $-0.92 | -9.5% | ✗ MISS |
Q1 2023 | Feb 23, 2023 | $-0.86 | $-0.87 | -1.2% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-1.02 | $-0.93 | +8.8% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.92 | $-0.81 | +12.0% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-1.13 | $-1.19 | -5.3% | ✗ MISS |
Q1 2022 | Feb 24, 2022 | $-0.83 | $-1.01 | -21.7% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-0.91 | $-1.06 | -16.5% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.93 | $-0.66 | +29.0% | ✓ BEAT |
Latest News
Leerink Partners Maintains Outperform on BridgeBio Pharma, Raises Price Target to $86
📈 PositiveBenzinga•Dec 15, 2025, 08:43 PM
Bernstein Initiates Coverage On BridgeBio Pharma with Outperform Rating, Announces Price Target of $94
📈 PositiveBenzinga•Dec 11, 2025, 10:54 AM
Wells Fargo Maintains Overweight on BridgeBio Pharma, Raises Price Target to $84
📈 PositiveBenzinga•Nov 11, 2025, 02:26 PM
Reported Saturday, BridgeBio Pharma Reports 69% Reduction In All-Cause Mortality And First Cardiovascular Hospitalization Through Month 30 In V142I Variant ATTR-CM
📈 PositiveBenzinga•Nov 10, 2025, 09:24 AM
JP Morgan Maintains Overweight on BridgeBio Pharma, Raises Price Target to $77
📈 PositiveBenzinga•Nov 7, 2025, 07:41 PM
BridgeBio Pharma To Present Data From Overall ATTR-CM Variant, V142I Populations from ATTRibute-CM At American Heart Association 2025
➖ NeutralBenzinga•Nov 3, 2025, 12:42 PM
HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $90 Price Target
📈 PositiveBenzinga•Nov 3, 2025, 11:48 AM
Goldman Sachs Maintains Buy on BridgeBio Pharma, Raises Price Target to $100
📈 PositiveBenzinga•Oct 31, 2025, 05:41 PM
TD Cowen Maintains Buy on BridgeBio Pharma, Raises Price Target to $95
📈 PositiveBenzinga•Oct 30, 2025, 08:10 PM
Raymond James Reiterates Outperform on BridgeBio Pharma, Raises Price Target to $71
📈 PositiveBenzinga•Oct 30, 2025, 02:34 PM
Cantor Fitzgerald Maintains Overweight on BridgeBio Pharma, Raises Price Target to $110
📈 PositiveBenzinga•Oct 30, 2025, 01:45 PM
Piper Sandler Maintains Overweight on BridgeBio Pharma, Raises Price Target to $98
📈 PositiveBenzinga•Oct 30, 2025, 01:34 PM
Truist Securities Reiterates Buy on BridgeBio Pharma, Raises Price Target to $80
📈 PositiveBenzinga•Oct 30, 2025, 12:32 PM
BridgeBio Pharma shares are trading lower after the company reported mixed Q3 financial results.
📉 NegativeBenzinga•Oct 29, 2025, 08:30 PM
BridgeBio Pharma Q3 EPS $(0.95) Misses $(0.89) Estimate, Sales $120.700M Beat $106.386M Estimate
➖ NeutralBenzinga•Oct 29, 2025, 08:02 PM
HC Wainwright & Co. Maintains Buy on BridgeBio Pharma, Raises Price Target to $90
📈 PositiveBenzinga•Oct 29, 2025, 05:44 PM
BridgeBio Pharma shares are trading higher after the company announced topline results from CALIBRATE, its global Phase 3 study of encaleret in autosomal dominant hypocalcemia type 1.
📈 PositiveBenzinga•Oct 29, 2025, 12:26 PM
Bridgebio Pharma Announced Topline Results From CALIBRATE Phase 3 Study Of Encaleret In Autosomal Dominant Hypocalcemia Type 1, Meeting All Pre-specified Primary And Key Secondary Efficacy Endpoints
📈 PositiveBenzinga•Oct 29, 2025, 11:11 AM
BridgeBio Pharma To Release Topline Phase 3 Results From Its Calibrate Trial For Autosomal Dominant Hypocalcemia Type 1 (ADH1) On October 28, 2025, Before Market Open
➖ NeutralBenzinga•Oct 28, 2025, 08:04 PM
HC Wainwright & Co. Maintains Buy on BridgeBio Pharma, Raises Price Target to $80
📈 PositiveBenzinga•Oct 28, 2025, 11:50 AM
Frequently Asked Questions about BBIO
What is BBIO's current stock price?
BridgeBio Pharma, Inc. (BBIO) is currently trading at $76.30 per share. The stock has moved +2.91% today.
What is the analyst price target for BBIO?
The average analyst price target for BBIO is $84.60, based on 1 analyst.
What sector is BridgeBio Pharma, Inc. in?
BridgeBio Pharma, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is BBIO's market cap?
BridgeBio Pharma, Inc. has a market capitalization of $14.54 billion, making it a large-cap company.
Does BBIO pay dividends?
No, BridgeBio Pharma, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorASND
Ascendis Pharma A/S
$199.99
Mkt Cap: $12.1B
BMRN
BioMarin Pharmaceutical Inc.
$61.15
Mkt Cap: $11.7B
EXEL
Exelixis, Inc.
$44.30
Mkt Cap: $11.9B
IONS
Ionis Pharmaceuticals, Inc.
$79.57
Mkt Cap: $12.6B
JAZZ
Jazz Pharmaceuticals plc
$166.99
Mkt Cap: $10.1B
MRNA
Moderna, Inc.
$33.80
Mkt Cap: $13.2B
RNA
Avidity Biosciences, Inc.
$72.34
Mkt Cap: $9.5B
ROIV
Roivant Sciences Ltd.
$22.41
Mkt Cap: $15.6B
RVMD
Revolution Medicines, Inc.
$78.78
Mkt Cap: $15.2B
SMMT
Summit Therapeutics Inc.
$17.82
Mkt Cap: $13.3B
Explore stocks similar to BBIO for comparison